Ocular Therapeutix, Inc. (OCUL)
7.565
+0.02
(+0.33%)
USD |
NASDAQ |
Oct 12, 16:00
7.58
+0.02
(+0.20%)
After-Hours: 20:00
Ocular Therapeutix Net Income (TTM) : -301.45M for June 30, 2026
Net Income (TTM) Chart
Historical Net Income (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | -301.45M |
| March 31, 2026 | -290.50M |
| December 31, 2025 | -265.94M |
| September 30, 2025 | -249.67M |
| June 30, 2025 | -216.75M |
| March 31, 2025 | -192.71M |
| December 31, 2024 | -193.51M |
| September 30, 2024 | -174.34M |
| June 30, 2024 | -138.36M |
| March 31, 2024 | -115.27M |
| December 31, 2023 | -80.74M |
| September 30, 2023 | -67.06M |
| June 30, 2023 | -90.73M |
| March 31, 2023 | -88.81M |
| December 31, 2022 | -71.04M |
| September 30, 2022 | -59.35M |
| June 30, 2022 | -32.50M |
| March 31, 2022 | -22.22M |
| December 31, 2021 | -6.553M |
| September 30, 2021 | -88.32M |
| June 30, 2021 | -102.92M |
| March 31, 2021 | -131.00M |
| December 31, 2020 | -155.64M |
| September 30, 2020 | -96.04M |
| June 30, 2020 | -102.88M |
| Date | Value |
|---|---|
| March 31, 2020 | -90.76M |
| December 31, 2019 | -86.37M |
| September 30, 2019 | -77.75M |
| June 30, 2019 | -73.99M |
| March 31, 2019 | -63.34M |
| December 31, 2018 | -59.98M |
| September 30, 2018 | -55.68M |
| June 30, 2018 | -56.24M |
| March 31, 2018 | -61.13M |
| December 31, 2017 | -63.39M |
| September 30, 2017 | -63.11M |
| June 30, 2017 | -57.14M |
| March 31, 2017 | -49.89M |
| December 31, 2016 | -44.70M |
| September 30, 2016 | -42.52M |
| June 30, 2016 | -44.45M |
| March 31, 2016 | -43.01M |
| December 31, 2015 | -39.75M |
| September 30, 2015 | -37.06M |
| June 30, 2015 | -32.84M |
| March 31, 2015 | -29.22M |
| December 31, 2014 | -28.66M |
| September 30, 2014 | -23.80M |
| June 30, 2014 | -19.72M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (TTM) Benchmarks
| EyePoint, Inc. | -306.64M |
| ANI Pharmaceuticals, Inc. | 99.95M |
| Eli Lilly & Co. | 26.71B |
| Corcept Therapeutics, Inc. | 54.20M |
| Veru, Inc. | -14.11M |